Mostrar el registro sencillo del ítem
dc.contributor.author
Chiavenna, Sebastián Matias
dc.contributor.author
Jaworski, Juan Pablo
dc.contributor.author
Vendrell, Alejandrina
dc.date.available
2019-03-29T21:57:09Z
dc.date.issued
2017-02
dc.identifier.citation
Chiavenna, Sebastián Matias; Jaworski, Juan Pablo; Vendrell, Alejandrina; State of the art in anti-cancer mAbs; BioMed Central; Journal Of Biomedical Science; 24; 1; 2-2017
dc.identifier.issn
1021-7770
dc.identifier.uri
http://hdl.handle.net/11336/72885
dc.description.abstract
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
BioMed Central
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
Cancer
dc.subject
Ctla-4
dc.subject
Egfr
dc.subject
Her2
dc.subject
Immunotherapy
dc.subject
Monoclonal Antibody
dc.subject
Pd-1/Pd-L1
dc.subject
Rank/Rankl
dc.subject
Solid Tumors
dc.subject
Vegf/Vegfr
dc.subject.classification
Medicina Critica y de Emergencia
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
State of the art in anti-cancer mAbs
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-03-29T12:06:43Z
dc.journal.volume
24
dc.journal.number
1
dc.journal.pais
Reino Unido
dc.journal.ciudad
Londres
dc.description.fil
Fil: Chiavenna, Sebastián Matias. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Ferrer Internacional. Ferrer Advanced Biotherapeutics; España
dc.description.fil
Fil: Jaworski, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Virología; Argentina
dc.description.fil
Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
dc.journal.title
Journal Of Biomedical Science
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1186/s12929-016-0311-y
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y
Archivos asociados